Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The company has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.

HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel.

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP) focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.

NITTO PHARMACEUTICAL INDUSTRIES is further contributing to human health and happiness .